arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Medicus Pharma Ltd.

MDCX

$0.31 ▲ +0.01 (+2.42%) at close

10 Visible periods

18 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Neutral Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Medicus Pharma Ltd. shows mixed fundamentals. Return on Invested Capital remain bright spots. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $9.2M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -512.2% ↘

FCF / Share $-0.30

Trailing P/E —

Price / Book 9.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-9.04M

↓ -77.2% —

FCF / Share Free cash flow per share

$-0.30

↑ +5.7% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

Return on Invested CapitalReturn on Invested Capital of 40181.0% is excellent on an absolute basis (target > 10%)

warning

Bearish Risks

Interest CoverageInterest Coverage of -155.01x is weak on an absolute basis (target > 5x)
FCF / Net IncomeFCF / Net Income of 0.48x is weak on an absolute basis (target > 1x)

Health Breakdown

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
EPS Growth YoY (%)	26.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-159.4% Weak → Weak Stable Year-over-year change in earnings per share Optimal: > 10%	-366.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	2.3% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	-100.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-77.2% Weak ↑ Weak Improving Year-over-year change in net income	-326.0% Weak ↑ Weak Improving Year-over-year change in net income	-818.7% Weak ↓ Weak Declining Year-over-year change in net income	-70.0% Weak Weak Year-over-year change in net income	-198.8% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	5.7% Fair ↑ Fair Improving Year-over-year change in free cash flow	—	-11.3% Weak ↑ Weak Improving Year-over-year change in free cash flow	-12.6% Weak Weak Year-over-year change in free cash flow	-120.9% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
FCF / Net Income (x)	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.44x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.32x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.36x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Return on Invested Capital (%)	-512.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	9110.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	0.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	-90.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—
Return on Capital (%) (%)	-115.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-77.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-0.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-50.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-90.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-63.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	—	—	—	—	—	-112.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-852%)	—	—	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Interest Coverage (x)	-22.94x Weak Weak Operating income divided by interest expense Optimal: > 5x	-28.56x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	-44.97x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-6.37M	$-8.71M	$-8.66M	$-9.67M	$-3.98M	$-4.16M	—	—	—	$-1.72M

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Basic EPS, GAAP (USD)	$-0.31	$-0.83	$-1.12	$-0.43	$-0.42	$-0.32	$-0.24	$-0.44	$-0.21	—
Free Cash Flow per Share (USD)	$-0.30	—	$-0.36	$-0.38	$-0.32	—	$-0.33	$-0.34	$-0.15	—
Book Value per Share (USD)	$0.03	$-0.00	$-0.04	—	—	$0.14	—	—	—	—
Tangible Book Value per Share (USD)	$0.03	$-0.00	$-0.04	—	—	$0.14	—	—	—	—
Basic Weighted Avg Shares (shares)	29.54M	—	18.63M	14.28M	12.24M	—	9.51M	8.17M	8.08M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Working Capital (USD)	$1.33M	$-47.42K	$-876.49K	$2.45M	$1.75M	$3.07M	—	—	—	$1.11M
Total Equity (USD)	$1.33M	$-67.55K	$-910.13K	—	—	$3.13M	—	—	—	—

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Net Income, GAAP (USD)	$-9.04M	$-15.07M	$-20.94M	$-6.18M	$-5.10M	$-3.54M	$-2.28M	$-3.63M	$-1.71M	—
Operating Cash Flow (USD)	$-8.97M	$-6.61M	$-6.76M	$-5.47M	$-3.94M	$-3.19M	$-3.10M	$-2.78M	$-1.18M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 10 quarters

Medicus Pharma Ltd.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare MDCX with peers